Compare Incyte Corporation (INCY) vs Altria Group Inc (MO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Altria Group Inc — how do they compare? Incyte Corporation trades at $117.96 (market cap $23.11B), while Altria Group Inc trades at $73.29 (market cap $124.67B). The key difference: Altria Group Inc is far larger — about 5.4× Incyte Corporation's market cap, and Altria Group Inc pays a 5.68% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | MO | |
|---|---|---|
Market Cap | $23.11B | $124.67B |
Sector | Health | Consumer Staples |
52-Week High | $118.52 | $74.66 |
52-Week Low | $67.38 | $54.72 |
Enterprise Value | $19.13B | $145.75B |
Dividend Yield | — | 5.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Altria (MO) trades at $74.14, down slightly by 0.09% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong profitability with a 39.52% net income margin and consistent dividend payments, including a recent $1.06 dividend declared for July 2026. Revenue remains stable around $20.1B for 2025, though net income dipped to $6.95B from prior peaks. Analyst consensus is predominantly bullish with 16 buys and a $71.00 price target.
Outlook: MO offers a high-yield dividend appeal and defensive positioning amid market volatility, but faces risks from declining smoking trends and regulatory pressures. Earnings beats in recent quarters provide support, though debt levels and competitive shifts in nicotine products warrant caution for long-term growth investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
